会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS
    • LMNA基因及其在HUTCHINSON-GILFORD PROGERIA SYNDROME(HGPS)和ARTERIOSCLEROSIS中的参与
    • US20080050837A1
    • 2008-02-28
    • US11870234
    • 2007-10-10
    • B. ErikssonFrancis CollinsLeslie GordonW. Brown
    • B. ErikssonFrancis CollinsLeslie GordonW. Brown
    • C12Q1/68C07H21/00G01N33/00
    • C07K14/47C12Q1/6883C12Q1/6886C12Q2600/136C12Q2600/156G01N2500/04Y10T436/143333
    • Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.
    • 本文公开了导致HGPS的LMNA基因中的点突变。 这些突变激活LMNA基因内的隐性剪接位点,导致部分外显子11的缺失和产生比正常蛋白短50个氨基酸的突变Lamin A蛋白产物。 除了新型Lamin A变体蛋白和编码该变体的核酸之外,使用这些分子检测与受试者的LMNA突变相关的生物学条件(例如,HGPS,动脉硬化和其他与年龄相关的疾病)的方法, 还描述了治疗这些病症,选择治疗方法,筛选影响Lamin A活性的化合物的方法,以及影响LMNA或LMNA变体表达的方法。 还提供了用于所述方法的实施例的寡核苷酸和其它化合物,以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂,例如抗体,以及 在诊断,治疗和筛查中使用这些抗体的方法。 还提供了用于实施本文所述方法的试剂盒。
    • 9. 发明申请
    • LMNA gene and its involvement in hutchinson-gilford progeria syndrome (HGPS) and arteriosclerosis
    • LMNA基因及其参与hutchinson-gilford progeria综合征(HGPS)和动脉硬化
    • US20050059071A1
    • 2005-03-17
    • US10943400
    • 2004-09-17
    • B. Maria ErikssonFrancis CollinsLeslie GordonW. Brown
    • B. Maria ErikssonFrancis CollinsLeslie GordonW. Brown
    • C07K14/47C12Q1/68
    • C07K14/47C12Q1/6883C12Q1/6886C12Q2600/136C12Q2600/156G01N2500/04Y10T436/143333
    • Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.
    • 本文公开了导致HGPS的LMNA基因中的点突变。 这些突变激活LMNA基因内的隐性剪接位点,导致部分外显子11的缺失和产生比正常蛋白短50个氨基酸的突变Lamin A蛋白产物。 除了新型Lamin A变体蛋白和编码该变体的核酸之外,使用这些分子检测与受试者的LMNA突变相关的生物学条件(例如,HGPS,动脉硬化和其他与年龄有关的疾病)的方法, 还描述了治疗这些病症,选择治疗方法,筛选影响Lamin A活性的化合物的方法,以及影响LMNA或LMNA变体表达的方法。 还提供了用于所述方法的实施例的寡核苷酸和其它化合物,以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂,例如抗体,以及 在诊断,治疗和筛查中使用这些抗体的方法。 还提供了用于实施本文所述方法的试剂盒。